Clinical • P1/2 data • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • JAK2 (Janus kinase 2) • RUNX1 (RUNX Family Transcription Factor 1) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • JAK1 (Janus Kinase 1) • SYK (Spleen tyrosine kinase)
|
TP53 mutation • KRAS mutation • NRAS mutation • FLT3-ITD mutation • IDH2 mutation • FLT3 mutation • NPM1 mutation • DNMT3A mutation • MLL mutation • SYK mutation • MLL-PTD
|
Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine • Rydapt (midostaurin) • entospletinib (GS-9973) • tuspetinib (HM43239)